Navigation Links
Wie die Operation am echten Patienten - Simulationsausbildung für Gefäßchirurgen und Kardiologen
Date:5/1/2013

CLEVELAND, May 1, 2013 /PRNewswire/ --

Die Simbionix USA Corporation, der weltweit führende Anbieter von Simulations-, Schulungs- und Ausbildungsprodukten für die Gesundheitsbranche, gibt stolz die Markteinführung verschiedener Ausbildungsmodule für den ANGIO Mentor™, den Simulator für endovaskuläre Eingriffe, bekannt.

     (Logo: http://photos.prnewswire.com/prnh/20120502/529202-a)

Der ANGIO Mentor von Simbionix ist ein innovatives, virtuelles, die Realität simulierendes Ausbildungssystem, das praktische Übungen in einer simulierten Umgebung für endovaskuläre Eingriffe bietet. Das System bietet eine multidisziplinäre Ausbildungslösung für eine Vielzahl von Verfahren. Eine stets wachsende Auswahl an Modulen unterstützt den Erwerb und das Verbessern grundlegender Fertigkeiten, um Selbstvertrauen und Kenntnisse bei endovaskulären Techniken und Verfahren zu gewinnen.

Das Lehren endovaskulärer Grundfertigkeiten erfordert viel Zeit und Aufmerksamkeit vom lehrenden Arzt und kann gefährlich sein, wenn es am lebenden Patienten durchgeführt wird. Der erste Satz der ANGIO Mentor-Module ist für angehende Ärzte konzipiert, die damit grundlegende Fähigkeiten für den Umgang mit dem Führungsdraht und die wichtigsten Elektrophysiologie-Kenntnisse erwerben. Diese Module werden in einer spielähnlichen Umgebung eingesetzt und machen das Lernen in einem benutzerfreundlichen, angenehmen und sicheren Umfeld möglich. Erstmals haben Ärzte die Möglichkeit, an einem nicht-anatomischen und einem anatomisch
'/>"/>

SOURCE Simbionix USA Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
2. Ultragenyx Relocates Company Headquarters to Support Operational Expansion
3. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
4. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
5. Surgical Information Systems Recognizes Clients for Financial, Clinical, and Operational Improvements
6. PRA Expands Operations in Europe
7. Premier healthcare alliance honors Atrium Medical Corporation for operational excellence
8. Dehaier Medical Announces Strategic Mutual Cooperation Agreement with HEYER Medical AG
9. Frazier Healthcare Acquires U.S. Commercial Pharmaceutical Packaging Operations from Catalent Pharma Solutions
10. Transonic Systems Selects Infinity Info Systems To Implement Microsoft Dynamics CRM To Drive Business Performance And Operational Excellence
11. PendoTECH Single Use Process Sensors Reduce The Environmental Impact Of Critical Bioprocess Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DIEGO , July 30, 2015  Tandem ... medical device company and manufacturer of the t:slim® ... has entered into non-exclusive Development Agreements with Dexcom, ... Tandem insulin pumps with the Dexcom G5 and ... "Integrating Tandem,s next generation pump platform with Dexcom,s ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... Argos Therapeutics, Inc. today announced that its late scientific co-founder ... Nobel Prize in medicine for the discovery of dendritic cells ... Steinman,s discovery of dendritic cells and his research of dendritic ... immunity have led to the development of Argos, core technology, ...
... Ingenious Med welcomes Chief Financial Officer, Mark Adams as ... responsible for the company,s financial, accounting, treasury and ongoing ... executive with high growth companies such as Ingenious Med," ... financial background and experience will bring tremendous value to ...
Cached Medicine Technology:Argos Therapeutics' Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System 2New Chief Financial Officer, Mark Adams, Joins Ingenious Med 2
(Date:7/31/2015)... ... ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in Seattle, ... it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a promising ... will grant 100% of the money raised to BioViva to help bring pioneering gene ...
(Date:7/31/2015)... ... July 31, 2015 , ... Successful Import/Export Programs:, Former FDA ... , Having FDA-regulated products held at ports costs time, money and the competitive ... or even destruction — of products, an FDA insider shows manufacturers how to ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida Hospital ... catheter that was developed for targeted delivery of fluids to selected sites in ... at Florida Hospital Tampa with the device that provides direct, local delivery of ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reputable ... The U.S. Women's National Soccer Team will face the Australia Women's National Team in ... 17th at Ford Field in Detroit and the second match will occur in Birmingham, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased to ... Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based call ... display logic shows the script components to the agent only when wanted, and allows ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2
... In a new study, researchers have discovered that suffering from ... which is a dangerous condition in which blood clots form ... cause an increase in the risk of heart attacks and ... of more than three million patient records from across the ...
... deal with crimes committed by drug addicts have been extended ... be started all across the country. // The drug courts ... 2002. These will undergo further monitoring by the Scottish Executive’s. ... indicated that there were no significant difference in re-conviction rates ...
... according to the decision taken by the Tibetan government in ... ,'Under an integrated development programme by 2007, $25 ... of the Tibetan government led by the Dalai Lama. ... India and some of them have taken around 20,000 acres ...
... of the brain plays an important role in distinguishing ... at the National Institutes of Health's (NIH) National Institute ... scans has found how the brain's outer layer, cortex, ... childhood stage, reflecting a high-level thinking circuitry. On the ...
... pain killing medication helps by halting the production of an ... cancer. The name of the painkiller is Nimesulide. // ... scientists found that derivatives of nimesulide stopped the production of ... of cancer is the most common breast cancer in postmenopausal ...
... Rudland, Dr Guozheng Wang and Dr Roger Barraclough from the ... new gene that causes the spread of cancer. // An ... is the main cause for the spread of cancerous cells ... If S100P is present it trigger the rapid spread of ...
Cached Medicine News:Health News:Cortex Of Youth With Superior IQ Matures Fast 2Health News:Pain-killer Drug Can Help Fight Breast Cancer 2
... Ultra High Throughput Screening (UHTS), Analyst ... performance. Allows for smooth transfer of ... by sharing all the detection modalities ... intensity, fluorescence polarization, time-resolved fluorescence, luminescence, ...
... OPTIMA is a fully automated microplate ... different measurement principles:, , Fluorescence Polarization ... Fluorescence , High-Performance Luminescence (flash ... ,It is designed for the ...
... From solution to cell based assays, ... any non-isotopic method of detection, Fusion is ... requirements plus the capability to use the ... detection modes in one system: Reads ...
VICTOR2 V measures prompt fluorescence, fluorescence polarization, luminescence, time-resolved fluorescence and absorbance. This model includes high density TRF (for 1536-well plates), temperature ...
Medicine Products: